Back to search results

Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.

Abroad (travel likely)RecruitingPHASE4

Conditions

Crohn's Disease

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • APHP - Hôpital Bicêtre, Le Kremlin-Bicêtre, PARIS, France

    Contact: Study coordinator (Aurélien AMIOT, PhD)
    Contact: Principal Investigator (Aurélien AMIOT, PhD)

  • CHU Amiens, Amiens, France

    Contact: Study coordinator (Mathurin FUMERY, PhD)
    Contact: Principal Investigator (Mathurin FUMERY, PhD)

  • CHRU Lille, Lille, France

    Contact: Study coordinator (Maria Nachury, MD)
    Contact: Principal Investigator (Maria Nachury, MD)

  • Chu Limoges, Limoges, France

    Contact: Study coordinator (Sophie GEYL, MD)
    Contact: Principal Investigator (Sophie GEYL, MD)

  • APHM, Marseille, France

    Contact: Study coordinator (Mélanie SERRERO, MD)
    Contact: Principal Investigator (Mélanie SERRERO, MD)

  • CHU Montpellier, Montpellier, France

    Contact: Study coordinator (Romain Altwegg, PhD)
    Contact: Principal Investigator (Romain Altwegg, PhD)

  • Hôpital de l'Archet II, Nice, France

    Contact: Study coordinator (Xavier Hebuterne, PhD)
    Contact: Principal Investigator (Xavier Hebuterne, PhD)

  • Assistance Publique - Hôpitaux de Paris, Paris, France

    Contact: Study coordinator (Mathieu UZZAN, MD)
    Contact: Principal Investigator (Mathieu UZZAN, MD)

  • CHU Bordeaux, Pessac, France

    Contact: Study coordinator (David LAHARIE, PhD)
    Contact: Principal Investigator (David LAHARIE, PhD)

  • Ch Lyon Sud, Pierre-Bénite, France

    Contact: Study coordinator (Stéphane NANCEY, PhD)
    Contact: Principal Investigator (Stéphane NANCEY, PhD)

  • CHU Rennes, Rennes, France

    Contact: Study coordinator (Guillaume BOUGUEN, PhD)
    Contact: Principal Investigator (Guillaume BOUGUEN, PhD)

  • CHU de Saint-Etienne, Saint-Etienne, France

    Contact: Study coordinator (Mathilde BARRAU, MD) · mathilde.barrau@chu-st-etienne.fr · (0)477829626
    Xavier ROBLIN, PhD (Sub-investigator)
    Contact: Principal Investigator (Mathilde BARRAU, MD)
Study leads

  • Mathilde BARRAU, MD

    Principal Investigator

    CHU de Saint-Etienne

View source on ClinicalTrials.gov(opens in a new tab)